Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

16.7%

1 terminated/withdrawn out of 6 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2

4(66.7%)

Phase 1

2(33.3%)

6Total

Phase 2(4)

Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT07052006Phase 2Active Not Recruiting

A Phase 2a Study of HT-6184 in Subjects With IPSS-R Very Low, Low or Intermediate Risk MDS and Anemia

Role: lead

NCT07399171Phase 2Not Yet Recruiting

Study to Evaluate the Effect of HT-4253 for the Prevention of Alzheimer's Disease in APOE4 Carriers

Role: lead

NCT07172867Phase 2Withdrawn

A Ph2 Study to Evaluate the Safety, Efficacy and Tolerability of HT-6184 and Semaglutide in Obese Participants With T2DM

Role: lead

NCT06537817Phase 1Completed

Study to Evaluate HT-4253 in Healthy Subjects

Role: lead

NCT06241742Phase 2Completed

Evaluating Ability of HT-6184 to Reduce Inflammation and Pain After Third Molar Extraction

Role: lead

NCT05447546Phase 1Completed

Study to Evaluate HT-6184 in Healthy Subjects

Role: lead

All 6 trials loaded